Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects-Reference-Cited by-同舟云学术

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects

Published:2018-02-05 Issue:3 Volume:7 Page:186-196
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Asaumi Ryuta¹,Toshimoto Kota²,Tobe Yoshifusa¹,Hashizume Kenta³,Nunoya Ken-ichi¹,Imawaka Haruo¹,Lee Wooin⁴,Sugiyama Yuichi²

Affiliation:

1. Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd.; Tsukuba Ibaraki Japan

2. Sugiyama Laboratory; RIKEN Innovation Center, RIKEN; Yokohama Kanagawa Japan

3. Drug Development Solutions Division, Sekisui Medical Co., Ltd.; Ibaraki Japan

4. College of Pharmacy and Research Institute of Pharmaceutical Sciences; Seoul National University; Seoul Korea

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Reference50 articles.

1. Clinical pharmacokinetics of rifampicin;Acocella;Clin. Pharmacokinet.,1978

2. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over;Acocella;a period of two weeks. Chemotherapy,1971

3. Pharmacokinetic interactions with rifampicin:;Niemi;clinical relevance. Clin. Pharmacokinet.,2003

4. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs;Maeda;Biol. Pharm. Bull.,2015

5. Predicting in vivo drug interactions from in vitro drug discovery data;Wienkers;Nat. Rev. Drug. Discov.,2005

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model;Clinical and Translational Science;2023-09-28

2. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment;Scientific Reports;2023-09-25

3. Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B;CPT: Pharmacometrics & Systems Pharmacology;2023-09-04

4. Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications;Metabolites;2023-07-29

5. A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept;Drug Metabolism and Disposition;2023-07-05